McGann M, Sacco A, Barnachea L. Evaluation of Extended-Release Oxycodone Administered through Enteral Tubes for the Management of Pain in Patients with Head and Neck Cancer: A Case Series [published online ahead of print, 2021 Sep 10]. J Pain Palliat Care Pharmacother. 2021;1-6. doi:10.1080/15360288.2020.1830224
Pub Category: Xtampza
Green JL, Robbins RS, Dailey-Govoni T, Butler SF. Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV®). J Pain Res. 2021;14:1773-1783. Published 2021 Jun 15. doi:10.2147/JPR.S304805
Geoffrey Severtson S, Kreider SED, Amioka EC, Margolin ZR, Iwanicki JL, Dart RC. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER. Pain Med. 2020;21(12):3660-3668. doi:10.1093/pm/pnaa272
Anderson N, Gillman AG, Wasan AD. Use of a Long-Acting Opioid Microsphere Formulation to Overcome Difficulties in Swallowing Pain Medication. J Pain Res. 2020;13:955?960. Published 2020 May 6. doi:10.2147/JPR.S249592
Gudin J. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza® ER (oxycodone DETERx® formulation): A review of published studies. J Opioid Manag. 2020;16(2):127?139. doi:10.5055/jom.2020.0559
McDonald AM, Spencer SA, Willey CD, et al. Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer [published online ahead of print, 2020 Apr 29]. Support Care Cancer. 2020;10.1007/s00520-020-05474-1. doi:10.1007/s00520-020-05474-1
Meske D, Kopecky EA, Passik S, Shram MJ. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER). J Opioid Manag. 2018;14(5):359?372. doi:10.5055/jom.2018.0468
Markman J, Meske DS, Kopecky EA, Vaughn B, O’Connor ML, Passik SD. Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone. J Pain Res. 2018;11:2051?2059. Published 2018 Sep 26. doi:10.2147/JPR.S168836
Fleming AB, Mayock SP, Saim S. Response to Crudele et al. Commentary on Mayock et al. “In Vitro Drug Release after Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations”. Clin Drug Investig. 2018;38(8):799?800. doi:10.1007/s40261-018-0664-y
Crudele N, Giordano J. Comment on Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations. Clin Drug Investig. 2018;38(8):795?797. doi:10.1007/s40261-018-0663-z